Personalized heparin calculator aims to speed up clot treatment

NCT ID NCT07250763

Disease control Sponsor: Inova Health Care Services Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a patient's gender, weight, and kidney function to calculate the starting dose of the blood thinner heparin gets patients to the right level faster than the standard flat rate. About 145 adults with blood clots, atrial fibrillation, or mechanical heart valves will receive a personalized starting dose. The goal is to see if this approach reduces time to effective treatment and lowers the risk of over- or under-dosing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: unfractionated heparin (blood thinner)
What this could lead to: If successful, this could make heparin treatment safer and more effective by reaching the right dose faster, reducing complications from clots or bleeding.
What could go wrong: This is a small, single-center study comparing against historical data, not a randomized trial. The personalized calculator may not work better in all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 145 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years-old * Diagnosis by the attending physician with one of the following conditions for which anticoagulation with heparin in an Food \& Drug Administration approved indication and considered the standard of care: * Moderate-intensity anti-Xa protocol: new-onset deep vein thrombosis or pulmonary embolism, or mechanical heart valve * Low-intensity anti-Xa protocol: atrial fibrillation, acute cardiac syndrome, embolic stroke * Heparin infusion either has not started or has been initiated in the last 120 minutes Exclusion Criteria: * Use of extracorporeal membrane oxygenation or ventricular assist devices such as Impella pumps * Diagnosis of thrombophilia/hypercoagulable state * Concurrent use of direct-acting oral anticoagulants or low molecular weight heparins * Baseline anti-Xa \> 0.7 * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute cardiac syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome atrial fibrillation intracranial embolism pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute cardiac syndrome Atrial fibrillation Deep vein thrombosis Mechanical heart valve recipients Pulmonary embolism

Personalized heparin calculator aims to speed up clot treatment

What the study statuses mean